Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.28 --0%
EPS Growth %: -31.3%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
CRMT, More
EPS Growth %: -31.3%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.55, $0.03 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $173.7 million versus the consensus estimate of $184.1 million.
GUIDANCE:
Emergent BioSolutions sees FY2018 EPS of $770.00-$800.00, versus the consensus of $741.00.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
